Projects

RNDr. Ingeborg Režuchová, PhD., MPH

National

Current
  • Characterization of the soluble form of carbonic anhydrase IX in molecular subtypes of breast cancer and its significance for prognosis.
    Program: VEGA
    Duration: 1. 1. 2024 – 31. 12. 2027
Finished
  • Interactions of calcium transport systems in carcinogenesis
    Program: SRDA
    Duration: 1. 7. 2021 – 30. 6. 2025
  • Clinical evaluation of prognostic and predictive value of tissue and serum Carbonic Anhydrase IX in breast cancer
    Program: Other projects
    Duration: 1. 11. 2019 – 31. 12. 2022
  • Study of pro-metastatic functions of carbonic anhydrase IX, relationship between CA IX and mucins and hypoxic microenvironment in pancreatic cancer.
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • The role of vitamin D and interferons type III in gammaherpesvirus oncogenesis
    Program: VEGA
    Duration: 1. 1. 2016 – 31. 12. 2019
  • Factors effecting production of cell-free Marek’s disease virus particles in vivo in chicken and in vitro in cell culture
    Program: VEGA
    Duration: 1. 1. 2014 – 31. 12. 2017
  • Characterization of novel motif in M1 protein of influenza A virus and using NS1 deletion mutants in tumor therapy
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 9. 2017
  • Murine gammaherpesvirus a producent of substances exhibiting immunomodulatory and antiproliferative properties
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 9. 2017
  • Murine herpesvirus, a model to study human oncogenic herpesviruses: viral imunomodulator M3 protein and factors important for virus spread among hosts
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • Study on induced reactivation of human oncogenic herpesviruses on the model of mice latently infected with
    Program: VEGA
    Duration: 1. 1. 2012 – 31. 12. 2015
  • Effect of hypoxia on replication of herpesviruses.
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2013
  • Study on novel protein modulator of immune response encoded by Murine gammaherpesvirus
    Program: VEGA
    Duration: 1. 1. 2010 – 31. 12. 2012
  • Characterization of a novel strain 4556 of Murine herpesvirus: model for study on human oncogenic herpesviruses pathogenesis
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2009
  • Study of the UL27.5 gene found located antisense of glycoprotein B gene essencial for Herpes simplex virus replication
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2009
  • Efficasy of an experimental recombinant vaccine against herpes simplex virus in animal model(s)
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees